OSI INITIATES PHASE I CLINICAL TRIAL OF PSN357.
"The science behind our research efforts is focused on the development of next-generation small molecule compounds designed to develop safer, more effective and innovative products for the treatment of metabolic diseases, particularly type 2 diabetes and obesity," stated Anker Lundemose, M.D., Ph.D., president of (OSI) Prosidion. "We believe PSN357's ability in pre-clinical studies to inhibit glycogen phosphorylase and reduce blood glucose levels may ultimately offer a competitive therapeutic option for diabetes patients."
This single-center, open-label Phase I study is scheduled to enroll up to 112 healthy volunteers. The study is a combined single and multiple dose escalation program that is designed to determine the safety and tolerability of PSN357. Study results will assist in facilitating design of a Phase II "proof-of-concept" clinical program in diabetes patients. The study is expected to last approximately three to six months.
The inappropriate over-production of glucose by the liver as a result of glycogen breakdown is a contributor to the hyperglycemia in type 2 diabetes. As the rate of glycogenolysis is regulated by glycogen phosphorylase (GP), inhibition of this key enzyme may constitute a therapeutic option for the treatment of type 2 diabetes. Pre-clinical data presented at the 2005 American Diabetes Association's Annual Scientific Session showed that PSN357 inhibits GP and reduces blood glucose levels in animal models with diabetes following acute and chronic dosing. An increase in liver glycogen was also seen in the study, however heart and skeletal muscle glycogen showed no changes from controls. In addition, a 9-day study in mice showed once daily oral administration of PSN357 maintained anti-hyperglycemic efficacy throughout the period. Other endpoints observed in the study were a 57 percent increase in liver glycogen and no changes in muscle glycogen or in levels of plasma insulin or alanine aminotransferase.
About OSI Pharmaceuticals
OSI Pharmaceuticals is committed to "shaping medicines and changing lives" by discovering, developing and commercializing high-quality and novel pharmaceutical products that extend life or improve the quality of life for cancer and diabetes patients worldwide. The company operates through two business teams, (OSI) Oncology and (OSI) Prosidion. (OSI) Oncology is focused on developing molecular targeted therapies designed to change the paradigm of cancer care. (OSI) Prosidion is committed to the generation of novel, targeted therapies for the treatment of type 2 diabetes and obesity. OSI's flagship product, Tarceva(R) (erlotinib), is the first drug discovered and developed by OSI to obtain FDA approval and the only EGFR inhibitor to have demonstrated the ability to improve survival in both non-small cell lung cancer and pancreatic cancer patients. OSI markets Tarceva through partnerships with Genentech, Inc. in the U.S. and with Roche throughout the rest of the world.
For additional information about OSI, visit http://www.osip.com or call 631/962-2000.
(OSI) Prosidion is the diabetes and obesity business team within OSI Pharmaceuticals dedicated to the discovery and development of novel drugs for the treatment of type 2 diabetes and obesity. (OSI) Prosidion's lead compound, PSN9301, is a Dipeptidyl Peptidase IV (DPIV) inhibitor currently in Phase II clinical trials. Two product candidates, both glucokinase activators, are scheduled to enter Phase I clinical trials in 2005. (OSI) Prosidion owns or has licensing rights to a portfolio of DPIV medical use patents with claims covering DPIV as a target for anti-diabetes therapy and the use of combinations of DPIV inhibitors with other anti-diabetes drugs such as metformin. A number of non-exclusive licenses to the patent estate have been granted to major pharmaceutical companies. (OSI) Prosidion operates through OSI's wholly-owned subsidiary, Prosidion Limited, in Oxford, UK.
For additional information about the business unit, please visit http://www.prosidion.com.
|Printer friendly Cite/link Email Feedback|
|Date:||Sep 1, 2005|
|Previous Article:||ONCOGENEX BEGINS FIRST OF 4 PHASE 2 CLINICAL 0GX-011 TRIALS.|
|Next Article:||VALEANT BEGINS CLINICAL DEVELOPMENT OF VIRAMIDINE IN JAPAN.|